Serum YKL-40 Levels Predict Endotypes and Associate with Postoperative Recurrence in Patients with Chronic Rhinosinusitis with Nasal Polyps

Sihui Wen*
Shenghao Cheng*
Shaobing Xie
Hua Zhang
Zhihai Xie
Weihong Jiang

Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central South University & Hunan Province Key Laboratory of Otolaryngology Critical Diseases, Changsha, Hunan, 410008, People’s Republic of China

*These authors contributed equally to this work

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a global health concern with high heterogeneity and rate of postoperative recidivation. YKL-40 is a pivotal pro-inflammatory mediator to promote Th2 immune response which is involved in many inflammatory diseases. This study aimed to investigate the predictive value of serum YKL-40 in CRSwNP endotypes and postoperative recurrence.

Methods: We recruited 80 primary CRSwNP, 40 recurrent CRSwNP patients and 40 healthy controls (HCs) in this study, and the serum and tissue specimens were collected. The middle turbinate mucosa tissue collected from patients undergoing septoplasty was used as control. Serum YKL-40 concentrations were detected by enzyme-linked immunosorbent assay (ELISA), and tissue YKL-40 mRNA and protein levels were examined using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). The difference of YKL-40 expression was compared among different group. Multivariate analysis and receiver operating characteristic (ROC) curve were performed to evaluate the value of serum YKL-40 in discriminating eosinophilic CRSwNP (eCRSwNP) and predicting postoperative recurrence.

Results: The serum YKL-40 levels in CRSwNP patients were higher than HCs, especially in eCRSwNP patients (p < 0.05). The elevated YKL-40 levels positively correlated with blood eosinophil percentage, tissue eosinophil counts and percentages (p < 0.05). The serum YKL-40 levels in recurrent CRSwNP patients were markedly enhanced than primary CRSwNP patients (p < 0.05). The YKL-40 mRNA and protein levels were significantly elevated in CRSwNP patients compared to HCs, especially in eCRSwNP and recurrent CRSwNP group. Multivariate analysis and ROC curve exhibited that serum YKL-40 might be a promising indicator in distinguishing CRSwNP endotypes and predicting postoperative recurrence.

Conclusion: Our data suggested that YKL-40 might be unregulated in CRSwNP and associated with mucosal eosinophilia and recurrence. Serum YKL-40 appeared to a novel biomarker for predicting CRSwNP endotypes and postoperative recurrence of CRSwNP.

Keywords: YKL-40, chronic rhinosinusitis, endotypes, recurrence

Introduction
Chronic rhinosinusitis (CRS) is a common chronic inflammatory disease of the upper airway, which affects about 15% of the adult population worldwide.\(^1\)

Depending on the presence of polyp, CRS is divided into two subgroups: chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps.
polyps (CRSsNP). Prior publications demonstrated that
T helper 2 (Th2)-driven inflammation was predominant
in the underlying pathomechanism of CRSwNP, while
T helper 1 (Th1)-driven inflammation was precipitated in
CRSsNP.\(^2\)\(^-\)\(^4\) CRSwNP can be further classified into eosi-
nophilic (eCRSwNP) and non-eosinophilic (neCRSwNP)
based on the degree of infiltration of eosinophils in nasal
mucosa.\(^1\)\(^5\) Currently, most scholars considered that the
tissue eosinophils percentage >10% of total inflammatory
cells was regarded as eCRSwNP, otherwise defined as
neCRSwNP.\(^6\)\(^7\) These two endotypes exhibited significant
differences in clinical characteristics, disease symptoms,
prognosis and postoperative recurrence rate. Given that,
preoperatively distinguishing eCRSwNP from CRSwNP
and predicting postoperative recurrence were essential to
develop personalized treatments and improve follow-up
protocols. It is urgent to find objective indicators or bio-
markers that can be used for differentiating eCRSwNP
from neCRSwNP and predicting for postoperative recur-
rence of CRSwNP before operation, which can provide
optimal treatment strategies and improve the prognosis.

YKL-40, also known as human chitinase-3 like-1, belongs
to a protein family containing an amino acid
sequence that is similar to the 18-glycosyl hydrolase of
bacterial chitinases.\(^8\) YKL-40 is secreted by a variety of
inflammatory cells, such as macrophages, vascular
smooth muscle cells, neutrophils,\(^9\) and it has been
demonstrated to be involved in many inflammatory dis-
eases, including chronic obstructive pulmonary disease
(COPD),\(^10\) lung fibrosis,\(^11\) asthma\(^12\) and COVID
infection.\(^13\) Recently, YKL-40 has been proved to be up-
regulated in the nasal mucosa of moderate/severe per-
sistent allergic rhinitis, associated with the remodeling
of nasal mucosa.\(^12\) Moreover, Ma et al’s study found
that the expression of YKL-40 in patients with
CRSwNP was higher than those in healthy control and
CRSsNP patients.\(^14\) Thus, we assumed that YKL-40
might play a vital role in the occurrence and develop-
ment of CRSwNP and contribute to discriminating
eCRSwNP from neCRSwNP, and predicting the post-
operative recurrence.

In this study, we aim to explore the change of serum
YKL-40 concentrations in primary CRSwNP and recur-
cent CRSwNP in comparison with healthy controls
(HCs), and assess its predictive potential in distinguishing
CRSwNP endotypes and predicting postoperative recurrence.

Materials and Methods
Participants and Settings
In the present study, 40 healthy controls and 120 CRSwNP
patients including 80 primary (43 neCRSwNP and 37
eCRSwNP) and 40 recurrent patients were recruited
between July 2019 and December 2019 in our department.
All participants met the diagnostic criteria of CRSwNP
according to the guidelines of the European Position
Paper on Rhinosinusitis and Nasal Polyps 2012.\(^15\) Exclusion
criteria for the study group included the following:
1) age <18 or >80 years; 2) patients with other nasal or
sinus diseases, such as fungal sinusitis, allergic fungal rhino-
sinusitis, cystic fibrosis and malignancy; 3) patients with
a diagnosis of inflammatory diseases, autoimmune diseases;
4) treated with immunotherapy, antibiotics, nasal or sys-
temic corticosteroids, or anti-allergic drugs within 4 weeks
before the surgery; 5) severe heart and kidney dysfunction;
6) aspirin intolerance and 7) pregnant condition. The diag-
nosis of recurrent CRSwNP was made when patients met
both of two criteria: 1) presence of nasal polyps detected by
nasal endoscopy and/or computed tomography (CT); 2)
symptoms lasting for more than 1 week despite treating
with normative intranasal corticosteroid.\(^16\) Forty age- and
gender-matched HCs who undergoing septoplasty with no
evidence of rhinitis or rhinosinusitis, diabetes mellitus,
severe heart and kidney dysfunction, or inflammatory or
autoimmune conditions were included as control group, and
their middle turbinate mucosa tissues were collected and
used as control. All subjects, except for the healthy controls,
underwent routine preoperative examination, blood tests,
nasal endoscopy, chest X-rays, electrocardiography and
high-resolution computed tomography (HRCT) or magnetic
resonance imaging (MRI). All CRSwNP patients scored
their nasal symptoms using the widely accepted visual
analogue scale (VAS) as previously described.\(^17\) Lund–
Mackay scoring system was used for preoperative CT
assessments.\(^18\)

Diagnosis of eCRSwNP and neCRSwNP
The nasal polyps were obtained from patients with
CRSwNP during the operation, then soaked in 10% for-
malin and embedded in paraffin. The embedded tissues
were sectioned into 5-μm sections by microtome and
stained with hematoxylin and eosin (H&E). Two indepen-
dent observers who were blinded to the clinical data
counted the numbers of eosinophils, lymphocytes, neutr-
ophils and plasma cells in 10 randomly selected high-power
fields (HPFs). eCRSwNP was diagnosed when the percentage of tissue eosinophils was higher than 10% of the total inflammatory cells, otherwise neCRSwNP was defined. 7

Sample Collection and YKL-40 Levels Measurement

Five milliliter fresh venous blood was collected from all subjects and stored at room temperature for 1 hour. Then, the blood samples were centrifuged at 3000 g at 4°C for 10 minutes. The supernatants were collected and stored at −80°C for subsequent experiments. Serum samples were thawed and centrifuged before use. Serum YKL-40 levels were detected by ELISA kit commercial (Multisciences, Hangzhou, China) according to the manufacturer’s instructions. All samples performed in duplicate to improve assay precision.

qRT-PCR Analysis

To further verify YKL-40 expression in tissue, we obtained 40 CRSwNP tissue specimens, including 20 primary nasal polyps and 20 recurrent nasal polyps from the middle meatus, and 40 middle turbinate mucosa samples from patients undergoing nasal septal surgery or cerebrospinal rhinorrhea surgery which were used as controls. Because the nasal polyps tissue originated from the middle meatus, which was anatomically adjacent to the middle turbinate, we collected middle turbinate mucosa as control. Tissue RNA was extracted with Trizol reagent (Thermo Fisher Scientific, Shanghai, China), and the RNA concentration was measured by Nanodrop 2000c (Thermo Fisher Scientific, Shanghai, China). RNA was reverse transcribed into cDNA using SureScript First-Strand cDNA Synthesis Kit (US EVERBRIGHT, Suzhou, China), according to the manufacturer’s instructions. qRT-PCR was performed using 100ng of cDNA with the SYBR Green qPCR Supermix (US EVERBRIGHT, Suzhou, China) to monitor DNA synthesis using specific primers. The primers used were shown in Table S1.

IHC of YKL-40

IHC was performed as previously described. 19 Sections were incubated overnight at 4°C with primary antibody against YKL-40 with a dilution of 1:200 (Affinity Biosciences, Changzhou, Jiangsu, China). Each section was incubated with a secondary antibody and then with horseradish peroxidase-labeled streptavidin complex (Zhongshan-Jinqiao, Beijing, China). The distribution of peroxidase is revealed by incubating in a solution containing 3% 3,3-diaminophetamine tetrachloride, which is then dyed back and covered with sulphide. During these processes, endogenous peroxidase was blocked with 0.3% hydrogen peroxide. Two representative images were selected in each group and showed at 200× and 400× magnification.

Statistical Analysis

Continuous variables with normal distribution were described as mean ± standard deviation (SD). For normally distributed variables, one-way analysis of variance (ANOVA) or Student’s t-test was applied. On the contrary, Kruskal–Wallis H-test or Mann–Whitney U-test was used. To evaluate the correlation between serum YKL-40 levels and clinical variables, Spearman correlation test was conducted. Logistic regression analysis and receiver operating characteristic (ROC) curves were performed to determine the predictive value of serum YKL-40 and other indicators. All statistical analyses were conducted on SPSS statistics software version 19.0 (IBM, Chicago, IL, USA), and figures were constructed in GraphPad Prism 7.0 (Software Inc. La Jolla, CA, USA). For all tests, P < 0.05 was considered statistically significant.

Results

Demographic and Clinical Characteristics of Participants

Among 80 primary CRSwNP patients, 43 (53.8%) patients were categorized into neCRSwNP group, and 37 (46.2%) patients were classified into eCRSwNP group. Demographic and clinical characteristics of all participants are shown in Table 1. Significant differences were observed in the rate of allergic rhinitis, blood eosinophil counts and percentages among three groups (p < 0.001). No statistical difference was observed in age, gender, rate of smoking, drinking, BMI among three groups, and preoperative VAS score and Lund–Mackay score between eCRSwNP group and neCRSwNP group. Typical histological figures of neCRSwNP and eCRSwNP are listed in Figure 1A and B, the eosinophils counts and percentages were significantly higher in eCRSwNP patients than neCRSwNP (all p < 0.001, Figure 1C and D).

YKL-40 Levels in CRSwNP Patients and Its Predictive Value in CRSwNP Endotypes

As shown in Figure 2, the serum YKL-40 levels were markedly increased in eCRSwNP and neCRSwNP groups.
in comparison with control group, and the YKL-40 levels were higher in eCRSwNP groups than neCRSwNP groups. Moreover, the elevated serum YKL-40 concentrations positively correlated with blood eosinophil percentages ($r = 0.221$, $p = 0.048$), tissue eosinophil counts ($r = 0.423$, $p = 0.005$), tissue eosinophil percentages ($r = 0.686$, $p < 0.001$) (Table 2). Logistic regression analysis results revealed that serum levels of YKL-40 (OR = 3.019, $p = 0.008$), blood eosinophil percentages (OR = 2.537, $p = 0.004$) and counts (OR = 2.134, $p = 0.030$), and comorbid allergic rhinitis (OR = 1.532, $p = 0.026$) associated with CRSwNP endotypes (Table 3). To further verify accuracy and predictive values of the serum YKL-40 levels, ROC curve analysis was applied. ROC curves (Figure 3) and their parameters (Table 4) indicated that serum YKL-40 exhibited potential predictive ability in CRSwNP endotypes.

### YKL-40 Levels in Recurrent CRSwNP Patients and Its Predictive Value in Postoperative Recurrence

Demographic and clinical characteristics between primary CRSwNP group and recurrent CRSwNP group are displayed in Table 5. Statistical differences were observed in comorbid allergic rhinitis ($p = 0.016$), blood eosinophil counts and percentages ($p < 0.001$), tissue eosinophil counts and percentages ($p < 0.001$) and neCRSwNP/eCRSwNP (p = 0.007) between the two groups, no significant difference was found in preoperative VAS score and preoperative Lund–Mackay score. As shown in Figure 4A, serum YKL-40 levels were elevated in recurrent CRSwNP group in comparison with primary CRSwNP group ($p < 0.01$), particularly in recurrent eCRSwNP group (Figure 4B). The variables with statistical difference in Table 5 were further included into logistic regression analyses (Table 6), and the results suggested that blood eosinophil percentages ($p = 0.009$), tissue eosinophil counts ($p = 0.024$), tissue eosinophil percentages ($p = 0.002$), neCRSwNP/eCRSwNP (p = 0.033), serum YKL-40 levels ($p < 0.001$) were associated with postoperative recurrence. The ROC analysis results showed that serum YKL-40 levels (AUC = 0.813) exhibited better accuracy and practicability in predicting the postoperative recurrence than other factors (Figure 5, Table 7).

### YKL-40 mRNA and Protein Levels in Nasal Tissues

The qRT-PCR result showed that the mRNA expression level of YKL-40 in CRSwNP patients was significantly higher than that in HCs ($p < 0.0001$), especially in eCRSwNP group (Figure 6A). No significant difference was seen between primary CRSwNP patients and recurrent CRSwNP patients ($p > 0.05$, Figure 6B). As IHC staining shown (Figure 7), the expression of YKL-40 was significantly up-regulated in CRSwNP group in comparison with HCs, especially in eCRSwNP and recurrent CRSwNP group, and YKL-40 protein was mainly located at the nasal epithelium and submucosa areas.

### Discussion

The present study firstly demonstrated that serum YKL-40 levels were increased in CRSwNP and associated with peripheral blood eosinophil counts and percentages, tissue eosinophil counts and percentages, and ROC

<table>
<thead>
<tr>
<th>Parameters</th>
<th>HC (n=40)</th>
<th>neCRSwNP (n=43)</th>
<th>eCRSwNP (n=37)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>43.3±12.5</td>
<td>43.1±9.1</td>
<td>43.8±10.2</td>
<td>0.976</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>23/17</td>
<td>26/17</td>
<td>22/15</td>
<td>0.962</td>
</tr>
<tr>
<td>Smoking (yes/no), n</td>
<td>10/30</td>
<td>13/30</td>
<td>9/28</td>
<td>0.802</td>
</tr>
<tr>
<td>Drinking (yes/no), n</td>
<td>7/33</td>
<td>4/39</td>
<td>4/33</td>
<td>0.493</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>23.1±2.3</td>
<td>23.3±1.6</td>
<td>23.5±1.9</td>
<td>0.815</td>
</tr>
<tr>
<td>Allergic rhinitis (yes/no), n</td>
<td>0/40</td>
<td>4/39</td>
<td>11/26</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Asthma (yes/no), n</td>
<td>0/40</td>
<td>2/41</td>
<td>6/31</td>
<td>0.014</td>
</tr>
<tr>
<td>Blood eosinophil counts (10⁹/L)</td>
<td>0.2±0.1</td>
<td>0.3±0.1</td>
<td>0.4±0.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Blood eosinophil percentage (%)</td>
<td>2.5±0.7</td>
<td>2.7±1.0</td>
<td>3.3±1.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Preoperative VAS score</td>
<td>NA</td>
<td>5.6±2.0</td>
<td>6.1±1.6</td>
<td>0.344</td>
</tr>
<tr>
<td>Preoperative Lund–Mackay score</td>
<td>NA</td>
<td>9.5±1.8</td>
<td>10.1±2.2</td>
<td>0.504</td>
</tr>
</tbody>
</table>

Abbreviations: neCRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; eCRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; HC, healthy control; BMI, body mass index; VAS, visual analogue scale; NA, not applicable.

https://doi.org/10.2147/JAA.S335964

DovePress

Journal of Asthma and Allergy 2021:14

1298

Wen et al

DovePress

Journal of Asthma and Allergy downloaded from https://www.dovepress.com/ by 35.160.112.80 on 04-Nov-2021

For personal use only.
curves and multivariate regression analysis showed that serum YKL-40 was closely associated with CRSwNP endotypes. The results of the qRT-PCR shown that the YKL-40 mRNA level was significantly increased in CRSwNP patients compared with HCs, and eCRSwNP group was significantly higher than neCRSwNP group. Interestingly, while YKL-40 expression level was higher in recurrent CRSwNP group than primary CRSwNP group, it was no significant difference, which may due to the small sample size. Furthermore, IHC analysis showed that YKL-40 was high expressed in nasal tissue of CRSwNP compared to HCs, especially in eCRSwNP and recurrent CRSwNP groups, which may involve in the course of CRS disease and associate with disease recurrence. Besides, serum YKL-40 were enhanced in recurrent CRSwNP patients in comparison with primary patients, and serum YKL-40 was a risk factor for post-operative recurrence. Taken together, these results indicated that serum YKL-40 may be an important biomarker for distinguishing CRSwNP endotypes and predicting recidivation.

YKL-40 is a pluripotent cytokine, which is expressed by immune as well as non-immune cells and tissues and secreted by neutrophils, B cells, monocytes, macrophages and epithelial cells.9,20 YKL-40 has been reported to be involved in the pathogenesis of various inflammatory and allergic diseases such as psoriasis, coronary artery atherosclerotic heart disease, asthma.21–23 Prior studies
demonstrated that elevated YKL-40 levels activated dendritic cells and promoted CD4+ T cells polarization, then aggravated airway remodeling in asthma patients.24–27

A recent study demonstrated that inhibition of the YKL-40 gene expression in asthmatic mice could alleviate eosinophilic airway inflammation, airway hyperreactivity, airway mucus secretion and significantly reduce the mRNA levels of IL-5, IL-13 and eotaxin.28 In another study, Kang et al found that YKL-40 contributed to the activation of Th2 inflammation and inhibited Th1 inflammation in comparison with YKL-40 null mutant (−/−) mice.29 In the present study, we observed that serum YKL-40 levels of CRSwNP patients were significantly higher compared to HCs, and elevated YKL-40 levels associated with the severity of eosinophilic inflammation in peripheral blood and tissues. We found that YKL-40 mRNA levels were significantly increased in CRSwNP patients; meanwhile,

### Table 2 Correlation Between Serum YKL-40 and Clinical Variables in CRSwNP Patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>r</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>0.039</td>
<td>0.729</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>−0.084</td>
<td>0.458</td>
</tr>
<tr>
<td>Blood eosinophil counts (10⁹/L)</td>
<td>0.200</td>
<td>0.075</td>
</tr>
<tr>
<td>Blood eosinophil percentage (%)</td>
<td>0.221</td>
<td>0.048</td>
</tr>
<tr>
<td>Preoperative VAS score</td>
<td>0.069</td>
<td>0.541</td>
</tr>
<tr>
<td>Preoperative Lund–Mackay score</td>
<td>0.011</td>
<td>0.929</td>
</tr>
<tr>
<td>Tissue eosinophil counts (n/HPF)</td>
<td>0.423</td>
<td>0.005</td>
</tr>
<tr>
<td>Tissue eosinophil percentages (%)</td>
<td>0.686</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyps; BMI, body mass index; VAS, visual analogue scale; HPF, high-power field.

### Table 3 Logistic Regression Analysis of Factors Associated with CRSwNP Phenotypes

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum YKL-40 level (ng/mL)</td>
<td>3.019</td>
<td>1.623–6.023</td>
<td>0.008</td>
</tr>
<tr>
<td>Allergic rhinitis (yes/no), n</td>
<td>1.532</td>
<td>1.136–2.264</td>
<td>0.026</td>
</tr>
<tr>
<td>Asthma (yes/no), n</td>
<td>1.721</td>
<td>0.896–3.532</td>
<td>0.239</td>
</tr>
<tr>
<td>Blood eosinophil counts (10⁹/L)</td>
<td>2.134</td>
<td>1.417–3.568</td>
<td>0.030</td>
</tr>
<tr>
<td>Blood eosinophil percentage (%)</td>
<td>2.537</td>
<td>1.312–5.072</td>
<td>0.004</td>
</tr>
</tbody>
</table>

Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyps; OR, odds ratio; CI, confidence interval.
we were able to observe the fact that compared with HCs and neCRSwNP groups, YKL-40 protein expression levels in the nasal epithelium and submucosa areas were significantly increased in eCRSwNP and recurrent CRSwNP through IHC results, which may further support it as a useful and credible marker for clinical testing.

<table>
<thead>
<tr>
<th>Variables</th>
<th>AUC (95% CI)</th>
<th>P</th>
<th>Cutoff Value</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum YKL-40 level (ng/mL)</td>
<td>0.790 (0.692–0.889)</td>
<td>&lt;0.001</td>
<td>30.8</td>
<td>0.639</td>
<td>0.831</td>
</tr>
<tr>
<td>Blood eosinophil counts (10⁹/L)</td>
<td>0.603 (0.477–0.728)</td>
<td>0.115</td>
<td>0.3</td>
<td>0.540</td>
<td>0.589</td>
</tr>
<tr>
<td>Blood eosinophil percentage (%)</td>
<td>0.743 (0.634–0.852)</td>
<td>&lt;0.001</td>
<td>2.7</td>
<td>0.791</td>
<td>0.647</td>
</tr>
</tbody>
</table>

**Abbreviations:** ROC, receiver operating characteristics; CRSwNP, chronic rhinosinusitis with nasal polyps; AUC, area under the curve; CI, confidence interval.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Primary CRSwNP (n=80)</th>
<th>Recurrent CRSwNP (n=40)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>43.4±9.6</td>
<td>47.1±12.3</td>
<td>0.075</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>48/32</td>
<td>23/17</td>
<td>0.845</td>
</tr>
<tr>
<td>Smoking (yes/no), n</td>
<td>22/58</td>
<td>12/28</td>
<td>0.831</td>
</tr>
<tr>
<td>Drinking (yes/no), n</td>
<td>8/72</td>
<td>3/37</td>
<td>0.750</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>23.4±1.7</td>
<td>22.9±1.6</td>
<td>0.108</td>
</tr>
<tr>
<td>Allergic rhinitis (yes/no), n</td>
<td>15/65</td>
<td>16/24</td>
<td>0.016</td>
</tr>
<tr>
<td>Asthma (yes/no), n</td>
<td>8/72</td>
<td>8/32</td>
<td>0.157</td>
</tr>
<tr>
<td>Blood eosinophil counts (10⁹/L)</td>
<td>0.3±0.1</td>
<td>0.4±0.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Blood eosinophil percentage (%)</td>
<td>2.9±1.0</td>
<td>4.2±1.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Preoperative VAS score</td>
<td>5.8±1.7</td>
<td>6.0±1.9</td>
<td>0.655</td>
</tr>
<tr>
<td>Preoperative Lund–Mackay score</td>
<td>9.8±2.2</td>
<td>9.4±2.2</td>
<td>0.305</td>
</tr>
<tr>
<td>Tissue eosinophil counts (n/HPF)</td>
<td>28.9±22.1</td>
<td>52.0±27.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tissue eosinophil percentage (%)</td>
<td>12.2±7.6</td>
<td>21.7±10.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>neCRSwNP/eCRSwNP</td>
<td>43/37</td>
<td>11/29</td>
<td>0.007</td>
</tr>
</tbody>
</table>

**Abbreviations:** neCRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; eCRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; BMI, body mass index; VAS, visual analogue scale; HPF, high-power field.

Figure 4 Comparison of serum YKL-40 level between CRSwNP and recurrent CRSwNP. (A) Serum YKL-40 levels were distinctly higher in the rCRSwNP than CRSwNP. (B) Serum YKL-40 levels were significantly increased in recurrent eCRSwNP compared with primary neCRSwNP, primary eCRSwNP, and recurrent neCRSwNP. *p < 0.05; **p < 0.01. ns, not significant.

**Abbreviations:** CRSwNP, chronic rhinosinusitis with nasal polyps; rCRSwNP, recurrent chronic rhinosinusitis with nasal polyps; eCRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; neCRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps.
Table 6 Logistic Regression Analysis of Factors Affected the Rate of Recurrence in CRSwNP Patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergic rhinitis (yes/no), n</td>
<td>2.101</td>
<td>0.977–4.012</td>
<td>0.253</td>
</tr>
<tr>
<td>Blood eosinophil counts (10⁰/L)</td>
<td>1.845</td>
<td>0.963–3.154</td>
<td>0.652</td>
</tr>
<tr>
<td>Blood eosinophil percentage (%)</td>
<td>2.012</td>
<td>1.301–3.016</td>
<td>0.009</td>
</tr>
<tr>
<td>Tissue eosinophil counts (n/HPF)</td>
<td>2.414</td>
<td>1.403–5.123</td>
<td>0.024</td>
</tr>
<tr>
<td>Tissue eosinophil percentage (%)</td>
<td>3.012</td>
<td>1.587–6.993</td>
<td>0.002</td>
</tr>
<tr>
<td>neCRSwNP/eCRSwNP</td>
<td>1.687</td>
<td>1.025–3.874</td>
<td>0.033</td>
</tr>
<tr>
<td>Serum YKL-40 level (ng/mL)</td>
<td>2.976</td>
<td>1.353–6.012</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyps; neCRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; eCRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; OR, odds ratio; CI, confidence interval; HPF, high-power field.

These results were in line with most previous publications. Therefore, we speculated that YKL-40 acted as crucial role in the pathogenesis of CRSwNP, but the specific mechanism remains unclear. Previous studies clarified that eCRSwNP is Th2 cytokines mediated chronic inflammatory response, and tissue eosinophils infiltration served as a main pathological feature of eCRSwNP. It has been reported that YKL-40 could be released by neutrophils, epithelial cells, eosinophils, macrophages, and IL-4 could significantly increase the YKL-40 production in human nasal epithelial cells in vitro. More importantly, the expression levels of YKL-40 were positively correlated with the levels of IL-5 and eotaxin in the ovalbumin treated epithelial cells, which were potent chemotactic factors for the recruitment of eosinophils, and promoted recruitment of inflammatory progenitor cells into tissues. Interestingly, we discovered that serum YKL-40 levels were higher in eCRSwNP group than neCRSwNP group, and the tissue mRNA and protein level of YKL-40 were significantly increased in eCRSwNP compared to neCRSwNP. ROC curves and multivariate regression analysis showed that serum YKL-40 level was a reliable indicator to distinguish eCRSwNP from neCRSwNP. Hence, we have reasons to believe that YKL-40 may play a pivotal role in eCRSwNP and can serve as an objective indicator for discriminating CRSwNP endotypes. Preoperative detection of serum YKL-40 may contribute to predicting CRSwNP endotypes and developing individualized therapy.

Although endoscopic sinus surgery bright significantly improved symptoms and quality of life in CRSwNP patients, most patients still suffered a high risk of recurrence. Mendelsohn et al found that CRSwNP patients accompanied with asthma suffered a high polyps recurrence rate at 5 years (45%), and other researchers reported that the short-term recurrence rates of CRSwNP ranged from 21% to 66%. Prior publications showed that the degree of inflammation and eosinophil infiltration in nasal polyps were closely associated with postoperative recurrence. Van Zele et al described that patients with elevated eosinophil counts, IL-5 and IgE levels in nasal biopsy specimens were more likely to undergo revision surgery. In the present study, we found that serum YKL-40 levels were elevated in recurrent CRSwNP group in comparison with primary CRSwNP group, particularly in recurrent eCRSwNP group, and increased YKL-40 levels correlated with tissue and peripheral blood eosinophils. Furthermore, we discovered that tissue mRNA expression level of YKL-40 was elevated in recurrent CRSwNP group in contrast with primary CRSwNP group. Meanwhile, IHC analysis demonstrated that YKL-40 protein expression was significantly increased in recurrent CRSwNP. These results were consistent with our serological results. Accordingly, circulating YKL-40 levels were positively correlated with the productions of IL-5 and eotaxin, which were effective chemokines for eosinophils recruitment. The high concentrations of YKL-40 in peripheral blood would promote eosinophils maturation and proliferation, and enhanced tissue infiltration of eosinophils, leading to poor prognosis and higher risk of recidivation of CRSwNP. Collectively, we deemed that serum YKL-40

Figure 5 Receiver operating characteristics curves of serum YKL-40 level (green line), tissue eosinophil counts (blue line), blood eosinophil percentage (red line), and tissue eosinophil percentage (orange line).
levels can be proposed as an objective biomarker to predict postoperative recurrence in patients with CRSwNP.

However, the present work is a preliminary study to explore the role of YKL-40 in CRSwNP, and further researches are needed to explore the accurate mechanisms of YKL-40, which will provide a theoretical foundation to develop therapeutic target and new drugs based on YKL-40, and contribute to achieving individualized and precise treatment for CRSwNP.

Our study has some limitations. First, the sample size is relatively small, and the participants are recruited from a single medical center, which may increase the risk of selection bias, and we did not perform a subgroup analysis to explore the effect of presence of aspirin intolerance and asthma on the YKL-40 expression. Second, there is no unified criterion regarding the diagnostic criteria of eCRSwNP and recurrent CRSwNP, which may limit the applicability of our findings. Third, due to the difficulty of recruiting a control group with exactly similar age during clinical practice, the inflammation may vary with age. Lastly, we only measured the circulating and tissue levels of YKL-40, and its concentration in nasal lavage fluid was not detected. Further multicenter prospective studies with larger sample size and unified diagnostic criteria are needed to confirm and support our findings in the future.

In summary, we firstly indicated the association between YKL-40 and CRSwNP, and demonstrated that YKL-40 expression was up-regulated in CRSwNP and associated with mucosal eosinophilia and recurrence. We also found that serum YKL-40 might be a potential candidate biomarker for preoperative distinguishing CRSwNP endotypes and predicting its recurrence. These findings contributed to understanding the underlying pathogenesis

Table 7 ROC Analysis Results of Indicators for Predicting the Recurrence of CRSwNP

<table>
<thead>
<tr>
<th>Variables</th>
<th>AUC (95% CI)</th>
<th>P</th>
<th>Cutoff Value</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue eosinophil counts (n/HPF)</td>
<td>0.709 (0.640–0.818)</td>
<td>&lt;0.001</td>
<td>35.0</td>
<td>0.562</td>
<td>0.841</td>
</tr>
<tr>
<td>Blood eosinophil percentage (%)</td>
<td>0.619 (0.506–0.732)</td>
<td>0.034</td>
<td>0.4</td>
<td>0.611</td>
<td>0.764</td>
</tr>
<tr>
<td>Serum YKL-40 level (ng/mL)</td>
<td>0.813 (0.750–0.895)</td>
<td>&lt;0.001</td>
<td>33.2</td>
<td>0.772</td>
<td>0.831</td>
</tr>
<tr>
<td>Tissue eosinophil percentage (%)</td>
<td>0.802 (0.717–0.888)</td>
<td>&lt;0.001</td>
<td>13.7</td>
<td>0.547</td>
<td>0.822</td>
</tr>
</tbody>
</table>

Abbreviations: ROC, receiver operating characteristics; CRSwNP, chronic rhinosinusitis with nasal polyps; AUC, area under the curve; CI, confidence interval; HPF, high-power field.

Figure 6 The mRNA expression levels of YKL-40 in the tissue of CRSwNP patient and health controls. The mRNA expression levels of YKL-40 among healthy controls, eCRSwNP and neCRSwNP patients. (A) The mRNA expression levels of YKL-40 in primary CRSwNP and recurrent CRSwNP patients. (B) *p < 0.05, **p < 0.01, ****p < 0.0001; ns, not significant.

Abbreviations: HC, health control; CRSwNP, chronic rhinosinusitis with nasal polyps; eCRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; neCRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps.
of eCRSwNP and recurrent CRSwNP, which could provide a novel and effective intervention target and improve precise treatment.

**Abbreviations**
CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with polyps; CRSsNP, chronic rhinosinusitis without nasal polyps; HCs, healthy controls; ELISA, enzyme-linked immunosorbent assay; qRT-PCR, quantitative real-time polymerase chain reaction; IHC, immunohistochemistry; ROC, receiver operating characteristic; eCRSwNP, eosinophilic chronic rhinosinusitis with polyps; neCRSwNP, non-eosinophilic chronic rhinosinusitis with polyps; Th1, T helper 1; Th2, T helper 2; COPD, chronic obstructive pulmonary disease; CT, computed tomography; HRCT, high-resolution computed tomography; MRI, magnetic resonance imaging; VAS, visual analogue scale; H&E, hematoxylin and eosin; HPF, high-power field; SD, standard deviation; ANOVA, one-way analysis of variance.

**Data Sharing Statement**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

---

**Figure 7** Immunohistochemical staining of YKL-40 in HC, eCRSwNP, neCRSwNP and rCRSwNP patients. (×200 and ×400 magnification). (A and B) HC group. (C and D) neCRSwNP group. (E and F) eCRSwNP group. (G and H) rCRSwNP group.

**Notes:** HC group specimen from the middle turbinate of same region. Each CRSwNP groups specimens from the nasal polyps of undergoing functional endoscopic sinus surgery.

**Abbreviations:** HC, healthy control; CRSwNP, chronic rhinosinusitis with nasal polyps; neCRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; eCRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; rCRSwNP, recurrent chronic rhinosinusitis with nasal polyps.
Ethics Approval and Consent to Participate
This study was conducted in accordance with the recommendations of Declaration of Helsinki. The Human Ethical Committee of Xiangya Hospital of Central South University approved this study, and the approval number is “201907812”. All participants provided informed consent.

Acknowledgments
This work was supported by National Natural Science Foundation of China (No. 81770985, No. 81800917 and No. 81873695) and Natural Science Foundation of Hunan Province (No. 2020JJ4910).

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure
The authors have declared that there is no competing interest in relation to this study.

References


